Conclusions The therapeutic scope of GLP-1R agonists is expanding beyond traditional metabolic targets, highlighting its potential for headache and pain disorders
Conflict of interest FG received research support from Eli Lilly, LifeScan, and Takeda and served as a consultant and author for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp and Dohme, Novo Nordisk, Roche Diabetes Care, and Sanofi
I like working, Gordon said
Subject of over 100 published peer-reviewed studies
They are pain-free with no downtime, no dietary restrictions, and no disruptions to your busy schedule required
Theyve really exploded in popularity with people using them for everything from weight loss to muscle preservation and faster healing